PTC Therapeutics (PTCT) Posts Q4 Loss of 84c/Share

PTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($0.84), $0.02 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $7.99 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c